Gain Therapeutics (GANX) Earnings Analysis
Gain Therapeutics (GANX) next reports earnings on 2026-08-11, consensus EPS -0.14 USD. Last quarter (2026-05-11) it beat with EPS -0.13 USD vs -0.13 USD est (0%). It has beaten estimates in 4/4 recent quarters (100%). Trailing P/E -3.17.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does GANX next report earnings?
| Next earnings date | 2026-08-11 |
|---|---|
| Consensus EPS estimate | -0.14 USD |
| Revenue estimate | 0.00B |
GANX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-11 | -0.13 USD | -0.13 USD | 0% | Beat |
| 2026-03-26 | -0.11 USD | -0.14 USD | +21.4% | Beat |
| 2025-11-12 | -0.15 USD | -0.15 USD | 0% | Beat |
| 2024-11-14 | -0.17 USD | -0.23 USD | +26.1% | Beat |
Beat rate: 4/4 (100%) over reported quarters with consensus data.
GANX valuation and analyst view
| Trailing P/E | -3.17 |
|---|---|
| Trailing EPS | -0.50295 USD |
| Price / book | 5.55 |
| Dividend yield | 0.00% |
| Market cap | 0.08B |
| Analyst consensus | Buy (7 buy / 1 hold / 0 sell) |
| Avg price target | 8.33 USD |
Related research pages
Frequently asked questions
When is Gain Therapeutics (GANX)'s next earnings date?
Gain Therapeutics is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -0.14 USD and revenue estimate of 0.00B.
Did GANX beat earnings last quarter?
In its 2026-05-11 report, GANX posted EPS of -0.13 USD versus a -0.13 USD estimate — a beat of 0%.
What is GANX's earnings track record?
Over the last 4 reported quarters with consensus data, GANX beat estimates 4 times (100%).
What is GANX's current P/E ratio and EPS?
GANX trades at a trailing P/E of -3.17 on trailing EPS of -0.5029516520954365 USD.
What do analysts rate GANX?
Analyst consensus is "Buy" across 8 ratings (0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 8.33 USD.